• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic touts 5-year economic analysis data from CRT-focused Reverse study

Medtronic touts 5-year economic analysis data from CRT-focused Reverse study

February 27, 2017 By Fink Densford

Medtronic Medtronic (NYSE:MDT) today released 5-year economic analysis data from its Reverse study of patients treated with cardiac resynchronization therapy devices, touting longer lifespans and long-term cost efficiency compared to optimal medical therapy.

Results from the Reverse trial were published in the Journal of the American College of Cardiology: Heart Failure.

“These new data expand upon the current evidence and guidelines for the treatment of heart failure, by showing that CRT in patients with mildly symptomatic heart failure is beneficial, both from a clinical perspective, as well as from a financial perspective. Reverse confirms that implanting CRT earlier slows the progression of heart failure, reduces heart failure-related hospitalizations and deaths, and prolongs life, all while being very cost-effective,” Dr. Michael Gold of the Medical University of South Carolina said in a prepared release.

Fridley, Minn.-based Medtronic touted Reverse as the largest study looking to explore the long-term clinical impact and survival benefit of CRT-D devices compared with CRT pacers, and as the 1st study to report cost-efficiency of CRT when implanted early in the disease state.

Economic analysis data from the 610-patient prospective, randomized, double-blinded Reverse study indicated that, under a Medicare setting, CRT is a cost-effective option for patients with mild-heart failure.

Medtronic said that results showed that patients receiving CRT therapy had an incremental cost effectiveness ratio of $8,840 per quality-adjusted life year when compared to those not receiving CRT therapy. Data also indicated that patients treated with CRT-D devices showed a 2.77 year improvement in survival compared to CRT-P devices, resulting in an ICER of $43,678 per QALY over a patient’s lifetime.

Data also indicated that CRT use delays disease progression, making CRT-Ds effectively cost-neutral compared to implanting an ICD initially, with a CRT-D to follow as the disease progresses.

“While CRT has long been established as a therapy that significantly improves outcomes for patients with heart failure, it is consistently underutilized. Not only does Reverse demonstrate the clinical benefit of CRT, it also quantifies the economic value of CRT, providing hospital systems with valuable information to help make informed decisions about CRT as a treatment option and the optimal timing of CRT for patients with heart failure. Ultimately, the goal is to increase value by improving patient outcomes and optimizing costs,” Medtronic heart failure biz GM Dr. David Steinhaus said in a press release.

Filed Under: Cardiovascular, Clinical Trials, Structural Heart Tagged With: Medtronic

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy